Abstract | BACKGROUND: METHODS: We performed CT volumetry of the spleen before and 12 weeks after FOLFOX/BEV and XELOX/BEV in 63 patients. The incidence of adverse events, haematological parameters, and biochemistry and urinalysis results were assessed during treatment. RESULTS: An increase in the splenic volume was not observed in the FOLFOX/BEV group, but was significant in the XELOX/BEV group (+5.0% vs. +18.8%, P=0.01). The APR before chemotherapy did not indicate the presence of splenomegaly in the 63 patients, however, it did significantly predict the development of grade 2 or higher adverse events during chemotherapy. CONCLUSIONS: An APR of 0.15 or higher before chemotherapy did not indicate the presence of splenomegaly, but could predict the development of adverse events due to FOLFOX/BEV and XELOX/BEV treatment.
|
Authors | Sumito Sato, Hiroshi Nakano, Yasuo Ishida, Takehito Otsubo |
Journal | Journal of gastrointestinal oncology
(J Gastrointest Oncol)
Vol. 4
Issue 2
Pg. 203-9
(Jun 2013)
ISSN: 2078-6891 [Print] China |
PMID | 23730517
(Publication Type: Journal Article)
|